Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy

Completed

Brief Summary: The purpose of this study is to analyze the influence of polymorphisms of the genes CLDN-1 (Claudina-1), LGALS3 (Lectin galactoside-binding soluble 3), SOCS3 (Suppressor of cytokine signaling 3), IL-28B (interleukin-28B), CCL5 (Chemokine C-C ligand 5) in the determination of clinical forms and in the percentage of cardiac fibrosis in patients with Chagas disease.

Detailed Description: The Chagas disease, in its chronic phase, can lead to the development of cardiac arrhythmias and dilated cardiomyopathy, which can evolve to heart failure, causing great morbidity and reduction on patient's quality of life. Some patients stay asymptomatic while others develop the cardiac form of the disease (chronic chagasic cardiomyopathy), or other forms, like the digestive (megacolon and megaesophagus) and the mixed form (cardiac and digestive).

The objective of this study is to analyze the association between single nucleotide polymorphisms with the clinical forms and the amount of cardiac fibrosis in patients with Chagas disease.

The polymorphisms will be analyzed by real time PCR (Polymerase Chain Reaction). The genes whose polymorphisms will be analyzed are: galectin-3, SOCS-3, IL-28B, CLDN-1 and CCL5.

The patients shall be accompanied in the specialized outpatient clinics for Chagas disease - Center of Biotechnology and Cell Therapy. They will be submitted to collection of blood samples for biochemical analysis and cardiac magnetic resonance imaging.

Recruitment & Eligibility

Inclusion Criteria

Chagas disease diagnosis confirmed by 2 different serologies
Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction

Exclusion Criteria

Significant aortic stenosis
Mitral stenosis with a valve area inferior than 1,5 cm2
Superior or moderated aortic and/or mitral regurgitation
Chronic use of immunosuppressive agents
Dialysis treatment of terminal renal failure
Fever on the last 48 hours or evidence of systemic infection in activity
Current abusive use of alcohol or illicit drugs
Any other comorbidities that impact patient's survival within the next 2 years
Liver disease in activity
Continuous use of steroids as treatment for chronic obstructive pulmonary disease
Hematologic, neoplastic or bone diseases
Homeostasis disturbances
Inflammatory diseases or chronic infectious diseases

Arm && Interventions

Group	Intervention	Description
Single group	Gathering of samples of genetic material	Group which contains all the patients of the study.

Primary Outcome Measures

Name	Time	Method
Presence of polymorphisms of the genes CLDN-1, LGALS3, SOCS3, IL-28B, CCL5 in the different forms of Chagas disease	The outcome measure will be assessed within one month of follow up.	We will evaluate the presence of polymorphisms of the genes CLDN-1, LGALS3, SOCS3, IL-28B, CCL5 in the different forms of Chagas disease.

Secondary Outcome Measures

Name	Time	Method
Presence of polymorphisms of the genes CLDN-1, LGALS3, SOCS3, IL-28B, CCL5 in subjects with and without myocardial fibrosis	The outcome measure will be assessed within one month of follow up.	We will evaluate the presence of polymorphisms of the genes CLDN-1, LGALS3, SOCS3, IL-28B, CCL5 in subjects with and without myocardial fibrosis assessed by magnetic resonance.

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial